Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial

CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, a single invitation for PSA screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years. However, the absolute reduction in deaths was small.TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN92187251.PMID:38581198 | DOI:10.1001/jama.2024.4011

Source: Cancer Control - April 6, 2024 Category: Cancer & Oncology Authors: Richard M Martin Emma L Turner Grace J Young Chris Metcalfe Eleanor I Walsh J Athene Lane Jonathan A C Sterne Sian Noble Peter Holding Yoav Ben-Shlomo Naomi J Williams Nora Pashayan Mai Ngoc Bui Peter C Albertsen Tyler M Seibert Anthony L Zietman Jon Oxle Source Type: research